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Abstract
The receptor for advanced glycation end products (RAGE) is a pattern recognition receptor (PRR)
that interacts with diverse endogenous ligands. Ligation of RAGE triggers a series of cellular
signaling events, including the activation of transcription factor NF-κB, leading to the production
of pro-inflammatory cytokines, and causing inflammation. While acute inflammation serves to
resolve pathogen infection and stresses, which promote tissue repair, persistent inflammation
results in maladaptive tissue remodeling and damage. RAGE signaling has been implicated in
multiple detrimental human illnesses including diabetes, atherosclerosis, arthritis, and Alzheimer’s
disease. In addition, prolonged inflammation often serves as the precursor for arterial remodeling
that underlies the exponential increase of age-associated arterial diseases. Despite the significant
progress and exciting discoveries in RAGE research, little is known on the biochemistry of RAGE
and the signaling mechanism of RAGE remains poorly defined. The biological impact of RAGE
signaling in clinical situations and aging-associated diseases also remains to be fully realized. This
review attempts to provide a comprehensive summary on both recent findings and missing pieces
of the RAGE puzzle.
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2. INTRODUCTION
Human innate immune responses are initiated through a group of PRRs termed Toll-like
receptors (TLR). Ligation of TLRs with corresponding patterned ligands triggers a series of
cellular signaling events, resulting in the production of pro-inflammatory cytokines and
local acute inflammation. Cytokine-mediated inflammation contains the invading pathogens
and activates the adaptive immune mechanisms, leading to pathogen clearance (1, 2). Until
recently, this evolutionally ancient mechanism was thought to serve as the first line of
defense that enables organisms to fight against pathogen infections. However, inflammation
has dual effects that can be both beneficial and adverse. The latter case occurs when
physiological homeostasis is perturbed. Under such situation, the acute inflammatory
response sustains, and chronic inflammation often results in significant tissue damage,
leading to chronic inflammatory disease states.
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It is still unclear how the body environment regulates immune clearance versus chronic
inflammation. Although pathogen infections often contribute to or exacerbate inflammatory
disease states, a clear etiology and the mechanistic link between pathogen infections and the
subsequent development of chronic inflammatory diseases have not been established.
Increasing evidence, however, suggests that endogenous “danger signals” generated by cell
necrosis, tissue injury, oxidative and environmental stresses, as well as aging, may provide
the basis for, or contribute to, the development of chronic inflammation-related diseases, e.
g. diabetes, atherosclerosis, arthritis, and Alzheimer’s disease (3-5). Two recent findings
support this view. First, TLRs also interact with endogenous ligands, e.g. high mobility
group box 1 protein (HMGB1, also termed amphoterin) (6, 7). HMGB1 remains intracellular
under normal physiological conditions, but is released into extracellular milieu as a “danger
signal” either during necrosis or under stressed conditions (8-10). Activation of leukocytes
also results in active secretion of “danger signals” including HMGB1 from these cells (10).
Another group of calcium binding cellular factors S100 (also termed calgranulin) seems to
play a similar role (11). The list of endogenous ligands that interact with the classical Toll-
like receptors is still growing (3, 12, 13). Second, a novel inflammatory signaling receptor,
RAGE, which interacts with a wide range of endogenous ligands, has been identified (14,
15).
RAGE, like TLRs, is expressed in tissues and cell types that are critical for immune
surveillance including lung, liver, vascular endothelium, monocytes, dendritic cells, and
neurons. RAGE and TLRs have overlapping ligands: HMGB1 is also a major ligand that
transduces signals via RAGE to cause inflammation. In addition to signaling, ligand-
activated RAGE also serves as an adhesion receptor that interacts with integrins and
facilitates the recruitment of pro-inflammatory leukocytes to the sites of inflammation,
further enhancing the inflammatory state (16, 17). Genetic studies also support the role that
RAGE plays in innate immunity: Ager ( the gene encoding for RAGE) knockout mice
exhibit resistance to septic shock, suggesting that RAGE, like TLRs, is also important for
innate immune responses (18). The genomic location of the Ager gene also suggests its
possible role in innate immunity: like the majority of components in the innate immune
system, Ager is encoded within the major histocompatibility (MHC) class III locus on
human chromosome 6 and mouse chromosome 17 (19, 20). Most recently, RAGE has been
found to complex with TLR9 and this complex detects pathogen DNA. The formation of
RAGE-TLR9 complex is mediated by HMGB1 (21). This finding implies that RAGE can
“team up” with other PRRs to facilitate the detection of either pathogens, or perhaps
endogenous “danger signals”. Similar to that of TLRs, RAGE signaling also impacts the
adaptive immunity, either directly or indirectly (22, 23). Together, these findings suggest
that RAGE functions as a “noncanonical Toll” that plays a role that is broadly involved in
innate immunity and disease development (24).
While ligands of TLRs known thus far are mainly derived from pathogens, most, if not all,
identified RAGE ligands do not originate from pathogens. In addition to HMGB1 and
S100s, advanced glycation end products (AGEs) are the major in vivo ligands that activate
RAGE to elicit inflammation (25). AGEs are proteins, lipids and polynucleotides modified
by nonenzymatic glycation and oxidation (26). These crosslinked and highly stable
complexes are resistant to enzymatic degradation (27). Examples of well-characterized and
widely studied AGEs inclu ε N-carboxymethyl-lysine (CML), pentosidine, and
methylglyoxal derivatives (28). Advanced glycation and oxidation increases during aging
and these processes are accelerated under physiopathological conditions such as
hyperglycemia (29-31). Thus, AGEs accumulated during aging may function as persistent
“endogenous danger signals” that set the stage for the manifestation of various
complications including those associated with cardiovascular diseases and diabetes in older
persons (32-34). In addition to their internal origin, AGEs are also derived from external
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sources such as heat-treated food (35) and environmental pollutions (36). Given such wide
range of ligands and its sites of expression, RAGE is likely to serve as the focal point that
integrates endogenous and exogenous danger signals that contribute to innate immunity-
elicited and aging-associated diseases.
RAGE ligand AGEs are formed by the Maillard reaction– a complicated, non-enzymatic,
and irreversible process that links reducing sugar groups to proteins, lipids and nucleic acids
(37). Such adducts are not only generated during pathological conditions such as
hyperglycemia and diabetes, but also during normal aging process, as various forms of AGE
have been detected in the aging tissues (38, 39). RAGE signaling has also been implicated in
the Alzheimer’s disease (40). Although conceivable, the role of RAGE signaling in aging
and aging-related diseases has not yet fully realized and well studied.
Arterial aging is characterized by intima-media thickening accompanied by central arterial
lumen increase (41). The accompanying structural and cellular changes in arterial wall are
characterized by endothelial dysfunction, vascular inflammation, smooth muscle cell
hyperplasia, and increased collagen and elastin degradation. These changes are often
associated with persistent inflammation that results in an increase of the stiffness of the
arterial wall in aging humans or animal models. Arterial aging is a dominant risk factor for
the development of cardiovascular diseases. Both AGEs and RAGE have been detected in
the intima, media and adventitia of the aorta, and aged tissues exhibit a clear increase of
AGEs, suggesting their age-dependent accumulation (42). A significant increase of AGEs
accumulation has been found in vascular tissues from diabetic patients (42) and, in
hypertensive subjects (43), an increased level of AGEs is associated with increased arterial
stiffness, independent of the blood pressure level.
3. BASIC STRUCTURE OF RAGE
Unlike TLRs, which share leucine-rich repeats in their extracellular portions, RAGE is a
member of the immunoglobulin (Ig) superfamily (15). Although the three-dimensional
structure of RAGE has not been solved, based on structural similarities to Ig, a basic picture
can be drawn: RAGE is a Type I membrane protein that has three Ig domains, a single
transmembrane spinning helix, and a short, highly acidic C-terminal cytosolic domain that is
required for the signal transduction (Figure 1) (11). The portion most distal to the
transmembrane anchor is the V-type domain that functions as the ligand-binding module
(44). Following the V-domain are two C-type domains. The functions of these two C-type
domains are unclear, although it has been proposed that the C1 domain adjacent to the V
domain may participate in ligand binding as well (45). It has been proposed that RAGE can
form cis homodimers (45, 46), or heterodimers with Mac-1 (also termed CD11B/CD18, or
αMβ2), a component of β2-integrin, either in cis, or trans configurations (16, 17). However,
since the former conclusion was based on studies of soluble RAGE (sRAGE, i.e. the RAGE
lacking membrane anchor and the cytosolic domain) expressed and purified from E.coli, the
molecular status of RAGE in its native state is still unknown. The domain (s)/region (s)
required for either cis- or trans- oligomerization have also not been clearly defined. It is also
unclear whether ligand binding will induce oligomerization of RAGE, as observed in several
other Ig superfamily members (47, 48), or modifications of its signal domain.
4. RAGE SIGNALING AND RAGE-MEDIATED INFLAMMATION
RAGE is not the only receptor that interacts with AGEs. Other PRRs, such as macrophage
scavenger receptors have been reported to interact with AGEs (49, 50). However, while
macrophage scavenger receptors show effective endocytosis upon ligation – a process that
disposes and clears the bound AGEs, RAGE ligation, in parallel to TLR ligation, mainly
promotes signaling and cellular perturbation, leading to inflammation (51). This property,
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along with a family of diverse endogenous ligands, has made RAGE not only a possible
alternative of the TLR, but also a distinct player in the development and progression of
inflammatory diseases and aging.
4.1. Signaling through RAGE
Similar to TLRs, activation of RAGE relays the cell surface signals to various intracellular
pathways including the NF-κB pathway, which is responsible for a myriad of transcriptional
programs leading to the production of pro-inflammatory cytokines. In addition to NF-κB,
among the known pathways that can be activated by RAGE are phosphoinositide 3-kinases
(PI3K)/Akt (also termed as protein kinase B), and mitogen-activated protein kinase
members (MAPKs) (52, 53). The latter group includes Jun-N-terminal kinase (JNK), p38,
and extracellular signal-regulated kinases (ERK) (54, 55) (Figure 2). These signaling
pathways often network to regulate the overall cellular responses to various stimuli, stresses
and environmental cues (56).
Because the expression of RAGE itself is also controlled by NF-κB transcription factors
(57), the activation of the RAGE-NF-κB signaling route results in an increased cell surface
expression of RAGE. Such a “feed forward” loop amplifies the initial signal and further
enhances inflammation (33, 58). The key step that activates NF-κB is the stimulus-
dependent, residue-specific phosporylation of NF-κB inhibitors, IκBs. This phosphorylation
is a prerequisite for the subsequent ubiquitination and proteasomal degradation of the
inhibitor (59). This unique regulatory mechanism does not require de novo cellular protein
synthesis. The kinase complex that is responsible for the specific phosphorylation of IκB is
the IKK signalsome (60). Although signals generated by different stimulus-receptor pairs
are relayed via different upstream cellular effectors, they eventually converge at the IKK
signalsome, which serves as the linchpin for the final few common acts to dismantle ΙκB
inhibitors that release, and activate NF-κB (61).
While various cellular effectors, especially those within the “first lap of the relay” that
transmit signals from TLRs, T-cell and TNFα receptors to NF-κB have been successfully
dissected and well studied, none of the cellular effectors in the RAGE signaling pathway has
been identified. Thus, despite studies clearly demonstrate that RAGE ligation activates NF-
κB (11, 17), the molecular mechanisms of such activation remain unknown. Since RAGE
possesses a unique cytosolic signal domain that does not share homologies with any of the
aforementioned receptors, one can hardly intuit that RAGE employs the same identified
initial effectors of these receptors as the first lap of the signal relay. It is possible though,
that RAGE may “cut into the line” by directly interacting with a common downstream factor
to pass the signal to the IKK signalsome (24).
4.2. Consequences of RAGE signaling
Experimental evidence and observations strongly suggest that RAGE signaling results in
profound inflammation (24, 62, 63). If RAGE is a “noncanonical Toll”, does RAGE
signaling simply manifest similar inflammatory consequences as TLRs, and thus reflect the
functional redundancy in the innate immune system? Available experimental evidence
apparently suggests otherwise. Ager-/- mice, although being resistant to septic shock, exhibit
osteosclerotic-like phenotypes with increased bone mass and bone mineral density, and
decreased bone resorptive activity (18, 64). Such deficiencies are due to the functional
disruption of the development of osteoclast precursor cells. Osteoclasts, like monocytes, are
derived from hematopoietic stem cells in the bone marrow, and signaling via RAGE in
osteoclasts has been shown to affect actin cytoskeletal reorganization and cell adhesion.
These steps are critical for the development of the osteoclast precursor cells towards
maturity (64). In addition, RAGE also plays a homeostatic role in lung development (65).
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These observations argue strongly that RAGE signaling, in addition to its “non-canonical
Toll” tasks, plays a distinct role in normal physiology.
Within the signaling realm, the role of RAGE seems to be unique in several aspects. First,
although RAGE shares certain ligand group such as HMGB1 with TLRs, it has not been
reported that other RAGE ligands such as AGEs, S100 and amyloid β-peptides also interact
with TLRs. Different ligands may elicit distinct signaling patterns from the same receptor,
and the selectivity of a ligand-receptor interaction in vivo is often subject to the exquisite
temporal and spatial regulation. For example, the outcome of RAGE stimulation by S100B
or by S100A6 differs: while S100B activates PI3/AKT kinase and NF-κB, S100A6
selectively activates JNK pathway, despite the fact both ligands are structurally identical and
belong to the same calcium-binding polypeptide superfamily (52). Second, it is possible that
RAGE and TLRs have different affinity to the same ligand. Endogenous ligands may have a
lower dissociation constant (Kd) when interacting with RAGE than with TLRs, whereas
ligands originating from pathogens bind TLRs tighter than they bind RAGE. Such ‘fine-
tuning” by the specific ligand-receptor affinity, and the formation of diverse signaling
complexes, may modulate the strength of the signal and determine which cellular signaling
pathway is activated. Hence, the overall cellular response is tightly regulated. A parallel
argument has been made that cytokines interleukin-4 and -13 influence the cell signaling
specificity by forming diverse signaling complexes with different ligand-receptor affinity
(66). Third, factors in a signaling pathway often exhibit multi-faceted of interactions that
lead to either “crosstalk” with other pathways or with components of the regulatory
circuitry. RAGE possesses a short, but highly charged, cytosolic signaling domain that bears
no homologies with TLR signal domains. This unique feature may render RAGE able to
attract distinct cellular factors, and hence open novel signaling and regulatory avenues.
How RAGE signaling elicits acute versus chronic inflammation is yet a remaining puzzle.
Two hypotheses are summarized in Figure 3. One hypothesis proposes that the
oligomerization status of RAGE ligands may play a role in eliciting acute versus chronic
inflammatory responses (51). Specifically, it has been suggested that monomeric RAGE
ligands generate the acute response, whereas oligomerization of RAGE ligands triggers
persistent signaling, resulting in chronic inflammation. In line with this hypothesis, it has
been shown that the S100B tetramer is much more effective in promoting cell survival than
its dimeric counterpart, and that tetramaric S100B binds sRAGE in vitro with higher affinity
than the dimeric form (46). To boot, it has been demonstrated that only multimeric forms of
S100 family members can trigger RAGE-mediated signaling and cellular activities (67, 68).
Nonetheless, although these observations argue that oligomeric forms of RAGE ligands are
required for eliciting signaling and cellular activities, they do not distinguish between acute
and chronic inflammation, and experimental evidence for this hypothesis is yet to come.
Alternatively, it can also be hypothesized, on the basis of the aforementioned receptor-
ligand affinity, that RAGE, may “team up” with TLRs to generate acute inflammation,
leading to rapid clearance of the invading pathogen (21). In contrast, in responding to
persistent endogenous danger signals with a low Kd, the receptor amounts chronic
inflammation. As noted, in vivo temporal-spatial regulation may be a critical determinant of
whether acute or chronic inflammation ensues. Thus, while both hypotheses are ligand-
selectivity based, the former stresses the configuration of ligands regardless their origin,
suggesting additional cellular regulations on the formation of the ligand’s molecular
patterns; the latter, in contrast, emphasizes the specific origin of ligands and implies that the
molecular pattern of a ligand is an inherent property. Systematic kinetic studies of RAGE-
ligand interactions and the duration of the signaling events may help to resolve the two
models, and provide some clues to understand this critical regulatory mechanism.
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5. RAGE-MEDIATED LEUKOCYTE RECRUITMENT AND EXTRAVASATION
In addition to signaling, ligand-activated RAGE also functions as an adhesion receptor in
leukocytes to facilitate their extravasation across the endothelial barrier (16, 17). Leukocyte
recruitment and infiltration through the vascular endothelium are primary processes of
inflammation, and are also the early steps of atherogenesis (69). Leukocyte recruitment to
the endothelium is significantly impaired in Ager-/- mice when they were artificially
induced by acute peritonitis effected by thioglycollate (16). Recruitment of leukocytes can
be restored by vascular endothelium-specific expression of RAGE in Ager-/- mice. Further,
RAGE-mediated leukocyte adhesion to endothelial cells in vitro is mediated by a direct
interaction between RAGE and the β2-integrin subunit Mac-1. Such interactions are
augmented by the addition of S100B ligand. Hence, this RAGE-Mac-1-dependent leukocyte
recruitment may be involved in the ICAM-1 (intercellular adhesion molecule 1)-independent
leukocyte transmigration as observed in the ICAM-1 deficient mice (70). The role of RAGE
ligands in leukocyte transmigration is further elucidated in another in vivo animal model
system in which administration of HMGB1 induces rapid neutrophil recruitment to the
endothelium in an ICAM-1 or fibrinogen-dependent manner (17). Curiously, although
S100B and HMGB1 both promote interactions between RAGE and Mac-1, S100B-induced
recruitment requires the expression of RAGE on endothelial cells (trans dimerization of
RAGE and Mac-1 between leukocytes and endothelial cells), whereas HMGB1-induced
neutrophil recruitment requires the expression of both RAGE and Mac-1 on neutrophils but
not on endothelial cells (cis dimerization of RAGE and Mac-1 on neutrophils) (16, 17).
RAGE-HMGB-1 interactions also enhance integrin-dependent homing of endothelial
progenitor cells to ischemic locations during vascular tissue repair (71).
The molecular mechanisms underlining such diverse cell recruitment strategies induced by
different RAGE ligands are obscure. HMGB1 seems to participate in the adhesion process
directly, by bridging RAGE and Mac-1, rather than simply promoting RAGE expression via
signaling, because ε N-carboxymethyl-lysine (CML), an AGE species that activates RAGE,
does not enhance RAGE-Mac-1 trans-interactions (16). It is still possible, though, that
HMGB1 promotes inflammation indirectly by eliciting cell signaling via other receptors
such as TLRs 2 and 4 (6, 7), leading to the expression of adhesion molecules that are
required for such recruitment on either leukocytes or endothelia. Although it has been shown
that HMBG1 resembles chemotactic factors and induces cellular lamellipodium formation
(17, 72, 73), whether RAGE mediates diapedisis, per se, also remains unclear. Given the
pathological significance of leukocyte transmigration in atherogenesis and arterial aging,
further studies on the molecular mechanism of RAGE-mediated cell migration are certainly
of importance.
6. RAGE AND ARTERIAL AGING AND DISEASES
Age-associated alterations in large arteries have been well documented in both human and
animal models (74-77). Clinical and experimental evidence suggest that these changes are a
dominant risk factor for the development of cardiovascular diseases in older persons (4, 75).
It has also been reported that the aged human arterial wall exhibits a proinflammatory
profile, with elevation of several cellular matrix proteins including matrix
metalloproteinases and monocyte chemoattractant protein-1 (78). Upregulation of these
proteins contributes to the development of cardiovascular diseases. Since the RAGE ligand,
HMGB1, also functions as a chemoattractant that facilitates the RAGE-dependent
transmigration of leukocytes across vascular endothelium (71, 73, 79, 80), it is likely that
RAGE, in addition to triggering inflammation, also participates in the subsequent cellular
remodeling events that may lead to the abnormal proliferation of vascular cells, or to the
formation of the atherosclerotic plaques. The former is a main cause for the age-associated
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thickening of the arterial wall, which may be a fertile soil in which arterial diseases can
develop. In addition, AGEs may exert biological effects other than signaling through RAGE
by adhering to extracellular matrix, thereby adversely affecting the structural integrity of the
vessel wall and the underlying basement membrane (62). Notwithstanding these
circumstantial clues linking RAGE signaling and RAGE-mediated leukocyte transmigration
to arterial aging, direct pathological studies on these aspects are yet to be undertaken.
6.1. RAGE signaling and arterial aging and diseases
The innate immune system has been implicated in cardiovascular diseases (81). How does
RAGE signaling, which also mediates innate immune response, contribute to arterial aging
and diseases? Activation of RAGE by its ligands results in a “feed forward” signaling mode
that upregulates RAGE expression and amplifies the cell signals. In diabetic apolipoprotein
E (apo E) deficient mice, RAGE signaling mediates prolonged vascular inflammation, and
enhances the expression of vascular cell adhesion molecule (VCAM)-1 and tissue factor,
leading to an exacerbation of the inflammatory state (82). In addition, blockade of RAGE
stabilizes established atherosclerotic plaques in diabetic apoE null mice (83). By functioning
as a co- or counter-receptor of the adhesion molecules, RAGE facilitates the recruitment of
leukocytes to the injured vascular tissues. This recruitment process establishes a basis for the
subsequent remodeling that may alter the integrity of vascular structure and function, thus
promoting atherogenesis.
RAGE signaling may also be connected to other signaling events that contribute to vascular
inflammation. For example, tumor necrosis factor (TNF)-α and 17β-estradiol (E2) can
enhance RAGE expression in human vascular endothelial cells, probably through the
activation of NF-κB (84). AGEs also induce the expression of vascular endothelial growth
factor (VEGF) in cultured microvascular endothelial cells, which confers additional cell
signaling events and potentially stimulates angiogenesis in vivo (85). Alagebrium (also
known as ALT7-11) is an AGE cross linkage breaker that has been demonstrated to improve
ventricular function and arterial compliance in both animal studies and in human trials (86,
87). Alagebrium not only reduces RAGE expression but also collagen accumulation in the
arterial tissue. A recent study has further demonstrated that alagebrium improves endothelial
function in patients with isolated systolic hypertension (88), and that this is correlated with a
reduction in inflammatory markers, suggesting that an anti-inflammatory effect may be a
mechanism for the beneficial effect. Similarly, reducing arterial stiffness and breaking the
AGE-RAGE nexus by alagebrium may help the overall reduction of inflammation and
arterial aging.
6.2. Soluble RAGE
Besides production of RAGE, the AGER gene can also be alternatively spliced to produce
several RAGE isoforms. The mRNAs encoding both N- and C-terminally truncated forms of
RAGE have been detected in human vascular endothelial cells, pericytes, and lung (89, 90).
The N-terminally truncated RAGE lacks the V-domain in the Ig-like extracellular portion,
and hence does not bind AGEs. This feature may contribute to the retardation of migration
of endothelial cell overexpressing N-terminally truncated RAGE (90). The observation
suggests that N-terminally truncated RAGE may regulate endothelial cell migration,
although the actual role of this isoform in vivo is subjected to further investigation. The C-
terminally truncated RAGE is often referred as endogenous secretory RAGE (esRAGE).
This variant receptor does not contain the transmembrane, and thus is secreted into the
extracellular milieu as a soluble protein. In addition to esRAGE, the native, cell surface
RAGE can be proteolytically cleaved to generate soluble RAGE (sRAGE) (91). Therefore,
in plasma, the population of soluble RAGE includes both esRAGE and sRAGE generated by
proteolytic “shedding” of native RAGEportion and the cytosolic signaling domain. The two
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species only differ in a small portion of their C-termini. The total circulating esRAGE and
sRAGE, the cleaved RAGE products, are often collectively referred to as sRAGE, regardless
of their origin.
How the two processes, which both lead to a higher level of soluble RAGE in plasma, are
regulated in vivo is currently unclear. Alternative splicing can be regulated either by
genomic structure of the AGER gene, and can be influenced by other trans cellular factors.
Inhibition of angiotensin converting enzyme (ACE) in rats increases the sRAGE level in
kidney, and this is associated with a decrease in RAGE expression (92). As noted, the
molecular mechanisms underlying this phenomenon are unclear, and the regulation of
sRAGE/RAGE ratio by angiotensin is likely to be indirect. Vigorous investigation on the
mechanism of sRAGE production is required to provide important insights that may foster
the development of therapeutic strategies to treat and prevent RAGE-linked diseases, and to
advance our understanding of arterial aging.
6.3. Role of sRAGE in vascular diseases and aging
Because all sRAGE species contain an intact N-terminal portion that encompasses the entire
Ig-like domains, they maintain the full capacity of ligand binding, yet are devoid of
signaling functions. These properties confer upon sRAGEs the status of a natural decoy for
the plasma membrane-anchored RAGE (93, 94), and a potential therapeutic tool for the
treatment of inflammatory diseases including diabetes and cardiovascular diseases. In mouse
diabetes models, administration of recombinant sRAGE suppressed formation of
atherosclerotic lesions at aortic sinus (94). Vascular inflammatory phenotypes such as
accelerated expression of VCAM-1, tissue factor, or matrix metalloproteinases in mice are
also prevented by sRAGE treatment (95). Administration of sRAGE also helps to stabilize
established atherosclerotic lesions in either diabetic or non-diabetic apoE-/- mice (83). Since
AGEs may also form adducts with extracellular matrix, they may affect the structural
integrity of the vessel in addition to signaling via RAGE (62). Thus, sRAGE may also
prevent such “non-specific” adverse effects of AGEs, especially during aging.
Various clinical studies have also been carried out to define whether the plasma level of
sRAGE (or esRAGE) is associated with cardiovascular and metabolic diseases (96). In
general, plasma sRAGE/esRAGE level appears to be lower in patients with hypertension,
atherosclerosis, cardiovascular diseases, and end-stage renal disease, suggesting that sRAGE
and/or esRAGE level can serve as biomarkers for these diseases (96). These observations, as
well as studies in animal models, suggest that genetically engineered recombinant sRAGE
can be used as a potential therapeutic blocker for the treatment and prevention of
inflammatory and metabolic diseases, or for modulating the inflammatory complications.
The plasma level of sRAGE also appears to affect human longevity (97). A high level of
plasma sRAGE is associated with extreme human longevity, suggesting a role of sRAGE as
an anti-aging reagent (97). But since this study measured the total soluble RAGE in the
plasma of the subjects, it is unclear whether such elevation is due to the contribution of
splicing (esRAGE) or to proteolytic cleavage of the wildtype RAGE (sRAGE).
7. CONCLUSIONS AND PERSPECTIVES
Since its discovery, RAGE has been implicated in several widespread chronic diseases that
share a common etiology of chronic inflammation. Increasing evidence suggests that RAGE,
as a PRR, functions as a “noncanonical Toll” that may not only act as a member of the
innate immune system for the defense against infections, but also respond to “endogenous
danger signals” generated by injuries and stresses, leading to persistent inflammation.
RAGE signaling-mediated chronic inflammation may also be an important contributing
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factor for arterial aging. Prior research has established the role of RAGE in various dire
inflammatory diseases, identified diverse range of RAGE ligands, and discovered possible
corresponding signaling pathways. More recent work has revealed the role of RAGE in
inflammatory cell recruitment and extravasation across endothelial barrier, and has further
implicated the receptor in the pathogenic process that results in vascular complications. The
pivotal role of RAGE in pathophysiological processes suggests that the receptor, as well as
its signaling network, is an attractive target for therapeutic interventions. In spite of these
exciting discoveries, a large void of RAGE signaling mechanisms prevails, as little is known
about these signaling mechanisms and none of the players within the signaling pathways has
been discovered. This, together with the lack of structure-function information of RAGE,
continue to stymie our understanding of RAGE-mediated acute versus chronic
inflammation. The AGER gene transcription regulation, e.g. the mechanism of alternative
splicing, or post-translational regulation, e.g. the proteolytic cleavage of RAGE at cell
surface, is also obscure. Future efforts on the biology of RAGE must include systematic
biochemical and molecular approaches that can reveal the mechanistic aspects of RAGE-
signaling and RAGE-ligand interactions. Insights drawn from such studies should help to
derive more effective strategies that may harness RAGE signaling towards beneficial, rather
than adverse, consequences. These efforts may also help to develop novel strategies to
modulate disease development and to shed light on our understanding of human arterial
aging.
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The basic structure of RAGE.
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Signaling via RAGE. RAGE is activated by its ligand, and signals are relayed to three
potential pathways. Among the identified signaling routes, NF-κB pathway is best studied
and is likely to play major role in RAGE signaling-mediated inflammation. Depending upon
ligand type, these pathways are either selectively activated, or, crosstalk, to regulate cellular
activities.
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Two possible strategies that differentiate RAGE-mediated chronic versus acute
inflammatory responses. A. The configuration of RAGE ligand regulates chronic versus
acute inflammation through RAGE signaling. Oligomeric ligands have higher affinity to
RAGE and elicit persistent signaling. In contrast, monomeric ligands bind RAGE poorly and
triggers acute response only. B. Ligand origin determines chronic versus acute
inflammation. While endogenous ligands possess patterns that have higher affinity to RAGE
and trigger chronic inflammation, the exogenous ligands have patterns with lower affinity to
RAGE, leading to acute responses and clearance.
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